Medrio Announces DIA Japan 2018 Attendance amid Strong Growth in Asia

Wednesday, November 7, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

At the event, Medio will showcase their innovative eSource platform, assert their position as the market leader for early-phase clinical trials, and expand their efforts to serve researchers in the Asia Pacific as the region becomes an increasingly desirable research destination.

SAN FRANCISCO, Nov. 7, 2018 /PRNewswire-PRWeb/ -- Medrio, the leading provider of eClinical technology for early-phase

pharma, medical device, and diagnostics clinical trials, will attend the 2018 DIA Japan Annual Meeting in Tokyo. Representatives from the company, including founder and CEO Mike Novotny, will be at booth 32/33 from November 11 – 13 to discuss clinical research and technology with attendees. Medrio product specialists will also be present at the booth, offering live demonstrations of Medrio's highly innovative integrated eSource and EDC platforms, as well as the company's new eConsent application released last month.

The conference comes as Medrio expands its presence in the Asia Pacific (APAC) region, taking advantage of an explosion in clinical trial activity there. The company recently opened an office in Tokyo, and has established Sales, Account Management, and Customer Success personnel across the region from Japan to Australia. By establishing this presence on the ground in Asia, Medrio is better able to stay attuned to the needs of new and existing APAC-based customers, and to deliver the tools, training, and support to facilitate their success. "Our expansion to the Asia Pacific is a great opportunity for us to bring not just our cloud-based software, but our Customer First principle to a rapidly-growing region for our industry," commented Mike Novotny, founder and CEO of Medrio. "Connecting face-to-face to understand the needs of clinical researchers no matter where they're located is a major part of who we are."

Medrio's expansion further reinforces Medrio's status as an eSource innovator, with numerous APAC-based organizations using Medrio eSource to streamline monitoring and improve site efficiency in Phase I clinical trials. At the conference, Medrio will host a 12:45PM luncheon seminar on November 12 in room 102, in which these organizations will discuss regulatory considerations, site efficiency, and other central aspects of their experience using eSource in early phase clinical research.

"We're excited to discuss paperless data entry and other eClinical efficiencies with the researchers at the conference," commented Shinya Yamamoto, Ph.D., Managing Director, APAC at Medrio. "Our eSource platform already has a strong record of bringing success to organizations in APAC, and we hope to expand upon that."

"With more organizations than ever before conducting innovative clinical trials in Asia, there has never been a better time for us to focus more of our efforts on serving this region," added Mr. Novotny. "We're excited to connect with these researchers at the DIA Japan Annual Meeting and discuss how we can serve them in their efforts to bring life-saving new medical products to market."

About Medrio Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.

SOURCE Medrio



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store